News

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide
Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...